The present invention provides for a method for the treatment of a respiratory disease, disorder or condition, or a viral infection or viral disease, disorder or condition in a subject, the method comprising the step of administering to said subject a medically active liquid in nebulized form by inhalation, wherein the medically active liquid comprises niclosamide or a pharmaceutically acceptable salt thereof and wherein the medically active liquid is administered in nebulized form using an inhalation device.

The present invention provides a single-dose powder inhalator and a method for the production thereof. It consists of an inhalator housing, which has a housing part (1), in which there is formed at least one medicament chamber (11) with a dose of a powdered medicament, and wherein the inhalator housing has an outlet opening (13′) and an outlet channel (13), which extends from the medicament chamber (11) to the outlet opening (13′). The outlet channel (13) is advantageously formed in the housing part (1). Also formed in the housing part (1) are an air inlet opening (12′), on a side of the medicament chamber (11) that is facing away from the outlet opening (13′), and an inlet channel (12), wherein the inlet channel (12) extends from the air inlet opening (12′) to the medicament chamber (11).

The invention provides a method of testing an inhaler based on performing an optical analysis of a dry powder medicament plume discharged from the inhaler upon actuation. More particularly, embodiments of the invention comprise illuminating the dry powder plume with a source of electromagnetic radiation and capturing one or more images of a pattern of radiation reflected or diffracted by the illuminated plume. The images are subsequently processed to determine and/or analyse one or more geometric and/or dynamic characteristics of the plume.

The invention provides a method of testing an inhaler based on performing an optical analysis of a dry powder medicament plume discharged from the inhaler upon actuation. More particularly, embodiments of the invention comprise illuminating the dry powder plume with a source of electromagnetic radiation and capturing one or more images of a pattern of radiation reflected or diffracted by the illuminated plume. The images are subsequently processed to determine and/or analyse one or more geometric and/or dynamic characteristics of the plume.

The invention provides a method of testing an inhaler based on performing an optical analysis of a dry powder medicament plume discharged from the inhaler upon actuation. More particularly, embodiments of the invention comprise illuminating the dry powder plume with a source of electromagnetic radiation and capturing one or more images of a pattern of radiation reflected or diffracted by the illuminated plume. The images are subsequently processed to determine and/or analyse one or more geometric and/or dynamic characteristics of the plume.

Described herein is a dry powder inhaler which includes: a reservoir containing a dry powder formulation and an arrangement for delivering a metered dose of the medicament from the reservoir; a cyclone deagglomerator for breaking up agglomerates of the dry powder medicament; a delivery passageway for directing an inhalation-induced air flow through a mouthpiece, the delivery passageway extending to the metered dose of medicament, and an inhalable β2-agonist having a particle size distribution of d10<1 μm, d50=1-3 μm, d90=3.5-6 μm and NLT 99% 10 μm and a lactose carrier.

Drug delivery devices that include a microphone and processing circuitry that can detect operating events, such as peak inspiratory flow (PIF) and Breath Actuated Mechanism (BAM) in dry powder inhalers can be used to improve clinical trials by providing information about the way in which the inhalers under test are being used.

Dry powder inhaler dose counters capable of making a display move swiftly between digits, in contrast to the progressive movement that occurs in simple gearing mechanisms.

A delivery device for and method of delivering a powdered substance, in particular a triptan, such as sumatriptan, to the posterior region of a nasal cavity of a subject, in particular for the treatment of headaches, for example, cluster headaches and migraine, and neuropathic pain, the delivery device comprising: a nosepiece for insertion into a nasal cavity of a subject through which the powdered substance is delivered to the posterior region of the nasal cavity of the subject, in particular the upper posterior two thirds of the nasal cavity; and a substance supply unit which is operable to deliver the powdered substance through the nosepiece.

This disclosure relates to nicotine powder inhalers where the nicotine powder is delivered at air flow rates that mimic a smoking regime.